Trelagliptin Succinate Cas 1029877-94-8
Triglitatin succinate is a dipeptidyl peptidase ⅳ (DPP-ⅳ) inhibitor developed by Takeda(Takeda Pharmaceutical Co., LTD.), which can selectively and continuously inhibit DPP-ⅳ and control blood glucose level. Clinical trials have shown that the drug has good safety and efficacy.
Introduction
After stimulation by oral ingestion, Our Trelagliptin Succinate Cas 1029877-94-8 increases the blood concentration of GLP-1 by inhibiting the activity of dipeptidyl peptidase-4 (DPP-4), which inactivates glucagon-like peptide-1 (GLP-1) in the intestine, thereby promoting the secretion of glucose-dependent insulin by the pancreas.
Our Trelagliptin Succinate Cas 1029877-94-8 increased active glp-1 concentrations in patients with type 2 diabetes mellitus with poor glycemic control during diet and exercise therapy, and we conducted a double-blind, placebo-controlled parallel group comparison trial. Trafiglitin 100 mg is taken orally once a week before meals for 12 weeks. Compared with the placebo group, there was a significant increase in the concentration of active GLP-1 in the glucose tolerance test after 12 weeks of administration.
Feature
Treagliptin succinate is a long-acting dipeptidyl peptidase-4 (DPP-4) inhibitor that inhibits DPP-4 activity. Trelagliptin reduces the breakdown of GLP1. In addition to causing a significant decrease in glycated hemoglobin in patients with type 2 diabetes, this product also lowers cholesterol and increases islet cell activity in patients with type 2 diabetes (T2D). In addition, if hypoglycemia occurs as a result of taking this drug, we can treat it with sucrose. On the other hand, hypoglycemia caused by glucosidase inhibitors should be treated with fructose.
Product Information
Name: Olaparib
.
